The deal priced below last closing price of $22.31. Jefferies and Leerink are acting as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Spyre Therapeutics price target raised to $36 from $27 at Stifel
- Apogee Therapeutics price target raised to $46 from $34 at Stifel
- Short Report: Bears boost exposure to Rocket Companies despite dovish Fed tilt
- Viridian Therapeutics price target raised to $36 from $35 at Oppenheimer
- 3 Best Stocks to Buy Now, 12/19/2023, According to Top Analysts
